Current characteristics associated with hereditary angioedema attacks and treatment: The home infusion based patient experience

被引:11
|
作者
Tachdjian, Raffi [1 ]
Banerji, Aleena [2 ]
Guyer, Autumn [2 ]
Morphew, Tricia [3 ]
机构
[1] Univ Calif Los Angeles, Los Angeles, CA USA
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Morphew Consulting LLC, Los Angeles, CA USA
关键词
C1 INHIBITOR DEFICIENCY; QUALITY-OF-LIFE; ECALLANTIDE TREATMENT; THERAPY; UPDATE; MANAGEMENT; BURDEN; RECOMMENDATIONS; EPIDEMIOLOGY; DEPRESSION;
D O I
10.2500/aap.2015.36.3832
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
This article presents a current perspective on the characteristics of hereditary angioedema (HAE) attacks and treatment as captured by a home infusion service. Retrospective data on 158 HAP patients who were enrolled in this acute treatment program were analyzed for factors surrounding an attack. The majority of patients had a high level of disease severity at baseline (88%), with a higher than expected likelihood of having a positive family history (87.8%). The most likely times for patients to call for home treatment were just before and during working hours (6:00 A.M.-5:00 P.M.). Eighty-three percent had more than one alternate mode of medication. Factors associated with a severe attack included an overall severe rating of HAP attacks in the previous year, an abdominal attack alone or a combination of peripheral and abdominal attacks versus a peripheral attack alone, and the use of two doses rather than one for treatment of the current attack. Average time to relief onset was 43.5 minutes. One dose of ecallantide was sufficient to treat the majority of attacks, and a second dose was needed in 23.6% of patients experiencing a severe attack. However, patients who reported both a severe attack rating during the previous year and experiencing only a peripheral current attack were more likely to experience a severe current attack. Acute treatment paradigms for HAP remain diverse. Understanding factors driving these decisions could help alleviate the overall burden of this disease and help overcome some of the challenges faced by the patients and their caretakers and improve their quality of life. Enhanced capture and analysis of prodromal factors in future studies should help us further alleviate the burden of this disease.
引用
收藏
页码:151 / 159
页数:9
相关论文
共 50 条
  • [31] Prophylactic Treatment in Hereditary Angioedema Is Associated with Reduced Anxiety in Patients in Leipzig, Germany
    Zarnowski, Julia
    Rabe, Marie
    Kage, Paula
    Simon, Jan-Christoph
    Treudler, Regina
    INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2021, 182 (09) : 819 - 826
  • [32] Current challenges and future opportunities in patient-focused management of hereditary angioedema: A narrative review
    Grumach, Anete. S. S.
    Gadir, Noga
    Kessel, Aharon
    Yegin, Ashley
    Martinez-Saguer, Inmaculada
    Bernstein, Jonathan. A. A.
    CLINICAL AND TRANSLATIONAL ALLERGY, 2023, 13 (05)
  • [33] Current status of the management of hereditary angioedema in China: a patient-based, cross-sectional survey
    Liu, Shuang
    Xu, Qun
    Xu, Yingyang
    Wang, Xue
    Zhi, Yuxiang
    EUROPEAN JOURNAL OF DERMATOLOGY, 2020, 30 (02) : 169 - 176
  • [34] Prophylaxis of Acute Attacks with a Novel Short-term Protocol in Hereditary Angioedema Patients Requiring Periodontal Treatment
    Ramaglia, Luca
    Isola, Gaetano
    Matarese, Giovanni
    Bova, Maria
    Quattrocchi, Paolina
    Iorio-Siciliano, Vincenzo
    Guida, Agostino
    ORAL HEALTH & PREVENTIVE DENTISTRY, 2020, 18 (02) : 355 - 361
  • [35] Sustained response of recombinant human C1 esterase inhibitor for acute treatment of hereditary angioedema attacks
    Bernstein, Jonathan A.
    Relan, Anurag
    Harper, Joseph R.
    Riedl, Marc
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2017, 118 (04) : 452 - 455
  • [36] Successful Long-Term Prophylactic Treatment With Subcutaneous C1 Esterase Inhibitor in a Patient With Hereditary Angioedema
    Hahn, Janina
    Nordmann-Kleiner, Melanie
    Trainotti, Susanne
    Hoffmann, Thomas K.
    Greve, Jens
    JOURNAL OF PHARMACY PRACTICE, 2020, 33 (06) : 907 - 911
  • [37] Treatment response after repeated administration of C1 esterase inhibitor for successive acute hereditary angioedema attacks
    Craig, Timothy J.
    Bewtra, Againdra K.
    Hurewitz, David
    Levy, Robyn
    Janss, Gerti
    Jacobson, Kraig W.
    Packer, Flint
    Bernstein, Jonathan A.
    Rojavin, Mikhail A.
    Machnig, Thomas
    Keinecke, Heinz-Otto
    Wasserman, Richard L.
    ALLERGY AND ASTHMA PROCEEDINGS, 2012, 33 (04) : 354 - 361
  • [38] Per-Attack Reporting of Prodromal Symptoms Concurrent with C1-Inhibitor Treatment of Hereditary Angioedema Attacks
    Prematta, Michael J.
    Bewtra, Againdra K.
    Levy, Robyn J.
    Wasserman, Richard L.
    Jacobson, Kraig W.
    Machnig, Thomas
    Craig, Timothy J.
    ADVANCES IN THERAPY, 2012, 29 (10) : 913 - 922
  • [39] Treatment of Hereditary Angioedema Attacks with Icatibant and Recombinant C1 Inhibitor During Pregnancy
    Roman Hakl
    Pavel Kuklínek
    Irena Krčmová
    Pavlína Králíčková
    Tomáš Freiberger
    Petr Janků
    Marcela Vlková
    Jiří Litzman
    Journal of Clinical Immunology, 2018, 38 : 810 - 815
  • [40] Nanofiltered C1 esterase inhibitor for treatment of laryngeal attacks in patients with hereditary angioedema
    Riedl, Marc A.
    Lumry, William R.
    Li, H. Henry
    Craig, Timothy J.
    Fitts, David
    Kalfus, Ira
    Uknis, Marc E.
    AMERICAN JOURNAL OF RHINOLOGY & ALLERGY, 2013, 27 (06) : 517 - 521